Lexeo Therapeutics, Inc. (LXEO) intrinsic value & 10-year financials
Lexeo Therapeutics, Inc. (LXEO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.64
- Market cap
- $141.6M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -51.5%
- Free cash flow (FY2025)
- -$99.0M
LXEO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$100.0M | -$1.86 | -$99.0M | — | -78.6% |
| FY2024 | — | -$98.3M | -$3.09 | -$81.6M | — | -234.6% |
| FY2023 | — | -$66.4M | -$2.07 | -$59.6M | — | 74.4% |
| FY2022 | $654.0K | -$59.3M | -$6.06 | -$55.2M | -9252.1% | 33.0% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Lexeo Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Lexeo Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 6.6% ROIC.
Lexeo Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Lexeo Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.